Search Bar & Filters
Found 20 Actively Recruiting clinical trials
Actively Recruiting
Researchers are investigating new treatments for advanced renal cell carcinoma RCC, a type of kidney cancer. This study compares a standard targeted therapy called belzutifan with a combination of belzutifan and another targeted therapy, zanzalintinib. The goal is to find out if adding zanzalintinib helps people with advanced RCC live longer and without their cancer worsening compared to belzutifan alone. Participants will be randomly assigned to one of two groups. One group will take 120 mg of belzutifan orally plus 60 mg of zanzalintinib once daily for about 24 months. The other group will take 120 mg of belzutifan plus a placebo matching zanzalintinib once daily for the same period. Both treatments are given as tablets taken by mouth. During the study, participants will have regular evaluations to monitor their cancers status, side effects, and quality of life. Researchers will use specific measures such as progression-free survival PFS and overall survival OS over up to 50 months. Other assessments include tumor response, duration of response, adverse events, and changes in health questionnaires related to physical function and symptoms. Safety and treatment effects will be carefully tracked throughout the study.
Actively Recruiting
Researchers are exploring a new treatment for chronic myeloid leukemia CML, a type of blood cancer. The study aims to evaluate the safety and tolerability of different doses of MK-4208 Tern-701 and to identify the highest dose that participants can tolerate and that may be effective in treating CML. This trial is being conducted in phases 1 and 2 to gather important information about MK-4208s use in this disease. Participants will receive MK-4208 orally at various doses ranging from 160 mg to 500 mg, taken once or twice daily depending on the study part. The study includes multiple groups that receive different doses to compare safety and tolerability. Treatment duration and dosing schedules may vary across the study parts, with careful monitoring of participants during the intervention. Throughout the study, participants will undergo regular assessments including monitoring for dose-limiting toxicities, adverse events, and serious side effects up to three years. Researchers will also track hematologic and molecular responses to the treatment and measure drug levels in the blood over time. Safety, tolerability, and efficacy data will be collected to better understand the potential role of MK-4208 in treating CML, with the study expected to last until 2030 for complete follow-up.
Actively Recruiting
Researchers are evaluating Enzomenib DSP-5336, an oral drug, in patients with various types of acute leukemia, including relapsed or refractory acute myeloid leukemia AML, acute lymphocytic leukemia ALL, and acute leukemia of ambiguous lineage. The study also includes patients with high-risk myelodysplastic syndromes MDS and relapsed multiple myeloma MM in selected sites. This phase 12 trial aims to assess the safety, pharmacokinetics, pharmacodynamics, and clinical activity of DSP-5336 alone or combined with standard AML treatments, particularly in patients with specific genetic mutations like MLL rearrangement or NPM1 mutation. The study involves dose escalation and dose expansion of DSP-5336 administered orally. Participants may receive DSP-5336 alone or combined with standard AML regimens such as venetoclax plus azacitidine or intensive chemotherapy with cytarabine and daunorubicin 73. Different study arms include patients with or without certain medications like CYP3A4 inhibitor azoles, and those with specific genetic profiles. The trial evaluates recommended phase 2 doses for various patient groups and combination treatments. Participants will undergo assessments including monitoring for adverse events within 30 days after the last dose and evaluation of clinical responses approximately six months after treatment begins. Researchers will collect blood and bone marrow samples for genomic analysis and track drug levels in the body. Safety labs, ECGs, physical exams, and patient questionnaires will be performed throughout the study. The trial includes long-term follow-up of overall survival up to two years after treatment ends, with visits and tests scheduled to monitor health and treatment effects.
Actively Recruiting
Researchers are evaluating zanidatamab for the treatment of adults with previously treated solid tumors that show high levels of HER2 protein IHC 3 overexpression. This phase 2, open-label study focuses on participants whose cancers have progressed despite prior systemic treatments and who have no confirmed beneficial treatment options left. Participants receive zanidatamab administered by intravenous infusion. The study includes participants with various HER2-expressing solid tumors, excluding biliary tract cancers. Some cohorts allow prior HER2-targeted therapy, while others do not. Treatment continues with monitoring for up to 2.5 years to evaluate response and safety. During the study, participants undergo regular assessments including tumor evaluations by independent central review and investigator assessment using RECIST 1.1 criteria. Researchers monitor objective response rates, duration and time to response, disease control, progression-free and overall survival, and treatment-emergent adverse events. Blood samples measure zanidatamab concentration and antibody development. Participants are followed for safety and treatment effects for up to 3.5 years.
Actively Recruiting
This trial investigates the use of ivonescimab compared to pembrolizumab as first-line treatments for patients with metastatic non-small cell lung cancer NSCLC whose tumors show high PD-L1 expression. The study focuses on evaluating overall survival and progression-free survival, aiming to understand how these treatments affect disease outcomes in this specific group. Participants will be randomly assigned to receive either ivonescimab or pembrolizumab as intravenous injections. Both treatments are administered as part of a double-blinded, phase 3 study, with a treatment period that may continue while monitoring the patients response and survival for up to approximately 36 months. Throughout the study, participants will undergo regular assessments including measurements of survival, disease progression, response rates, and monitoring for adverse events and laboratory abnormalities. Researchers will collect data on the duration of response and disease control, with safety follow-up continuing up to 30 to 90 days after the last treatment dose or initiation of other anticancer therapies. The overall study period extends until June 2029.
Actively Recruiting
Gynecological cancers such as ovarian, uterine, and cervical cancers significantly impact womens health, particularly through chronic pelvic pain caused by treatments like radiotherapy and chemotherapy. This pain is often difficult to manage and can reduce quality of life. Researchers are studying how ozone therapy, a complementary treatment, affects gene expression and epigenetic changes to better understand its role in pain relief. The study observes two groups of adult women with gynecological tumors treated by radiotherapy or chemotherapy those with chronic pelvic pain receiving compassionate ozone therapy and those without such pain. No experimental treatments are given as part of the study patients continue with their standard care. The research focuses on analyzing gene expression and biological age through epigenetic clocks before and after ozone therapy in the pain group, comparing these markers between the two groups. Participants will be evaluated at the start and after 16 weeks, with assessments including gene expression, biological age markers, pain scores, quality of life questionnaires, toxicity grading, and biochemical markers of oxidative stress and inflammation. The study aims to link these molecular changes to clinical outcomes to better predict pain responses. The total study duration extends until August 2027, with ongoing monitoring of patient health and well-being throughout.
Actively Recruiting
Chemotherapy-induced peripheral neuropathy CIPN is a common and challenging side effect of chemotherapy that can reduce treatment effectiveness and lower patients quality of life. Effective treatments for CIPN are limited, and this study explores the possible benefits of rectal ozone therapy as well as the role of the gut microbiome in CIPN severity and treatment response. The study is an observational analysis linked to a randomized clinical trial called OzoParQT, focusing on adult patients with any tumor type experiencing CIPN-related numbness or tingling. Participants receive standard care for their CIPN symptoms combined with 40 sessions of rectal insufflation of an O3O2 gas mixture over 16 weeks. One group receives ozone therapy with increasing O3 concentrations from 10 to 30 gmL, while the control group receives oxygen only placebo. The study aims to compare gut microbiome profiles between patients who improve symptomatically and those who do not, and between those receiving ozone therapy and placebo. During the 16-week study period, participants provide stool samples for gut microbiome analysis and complete questionnaires assessing neuropathy severity, quality of life, anxiety, depression, and biochemical markers of oxidative stress and inflammation. Researchers measure changes in patient-reported numbness and tingling, neuropathy severity scales, toxicity grades, and quality of life scores from baseline to the end of therapy. The study also monitors biochemical markers and psychological status to better understand the relationship between gut microbiome composition and CIPN.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of the Myval Transcatheter Heart Valve THV Series compared to Contemporary Valves, including the Sapien THV Series and Evolut THV Series, in patients with severe symptomatic native aortic valve stenosis. This multinational, prospective, randomized trial involves 768 participants and aims to assess whether the Myval device performs at least as well as the other commercially available valves in improving heart valve function. Participants will be randomly assigned to receive either the Myval THV Series or one of the Contemporary Valves via a transfemoral approach. The Myval devices come in various sizes ranging from 20 mm to 29 mm, with additional registries for extra-large sizes. Separate study groups include a non-randomized nested registry for extra-large Myval devices and a lead-in set to ensure procedural adherence by investigators before enrolling subjects. During the study, participants will undergo assessments including clinical evaluations and imaging to monitor valve function and safety over time. Outcomes measured include a combined safety and effectiveness endpoint at 30 days, as well as longer-term monitoring for mortality, stroke, kidney injury, valve performance, and quality of life up to 10 years. The study involves follow-ups at multiple timepoints to comprehensively evaluate the devices performance and patient health.
Actively Recruiting
This research aims to collect detailed, long-term information about patients with Lysosomal Acid Lipase LAL Deficiency, a rare genetic disorder caused by a deficiency of the enzyme responsible for breaking down certain fats in the body. The condition can present as a severe and rapidly progressing disease in infants or a more chronic illness in children and adults, affecting the liver, spleen, and lipid levels, and leading to serious health complications including liver damage and cardiovascular risks. The study focuses on understanding the diseases natural history and variability to improve patient care worldwide. This is an observational, multi-center, international disease registry where patients diagnosed with LAL Deficiency, regardless of their treatment status, are followed over time. The registry collects real-world data to evaluate the long-term outcomes and effectiveness of treatments including sebelipase alfa. Participation is voluntary for both patients and physicians, and the study includes patients living with the disease as well as those deceased. Participants contribute data through their regular medical care and follow-up visits, with researchers gathering information about disease progression, treatment responses, and clinical outcomes. The primary goal is to enhance knowledge about LAL Deficiency by monitoring varied patient experiences and health changes over time. The study is ongoing and aims to support clinical practice and regulatory commitments related to sebelipase alfa therapy. The total duration of participation varies based on ongoing data collection.
Actively Recruiting
Researchers are evaluating a combination of oral decitabine and ivosidenib as a first-line treatment for adults with newly diagnosed acute myeloid leukemia AML who have an IDH1 R132 mutation. This study focuses on older adults aged 60 years and above, or adults aged 18 years and older with specific health conditions that make them unsuitable for standard intensive chemotherapy. The main goals are to assess the rates of complete remission and incomplete marrow recovery, as well as to monitor the occurrence and severity of any adverse events. Participants will receive treatment cycles lasting 28 days, consisting of oral ivosidenib taken daily for 28 days and oral decitabine-cedazuridine tablets taken once daily for the first 5 days of each cycle. During screening and the first two treatment cycles, hydroxyurea or cytarabine may be used to control high white blood cell counts. Those who achieve remission may be eligible for allogeneic stem cell transplantation, after which they can resume ivosidenib treatment from day 60 post-transplant, continuing for up to two years. Throughout the study, participants will have regular assessments to monitor their response to treatment, including disease progression and any side effects. Those undergoing transplant will have additional evaluations before and after the procedure, including minimal residual disease statistics. The researchers will measure remission rates over three years, along with overall survival, event-free survival, quality of remission, and early mortality. Participants are followed until disease progression, unacceptable toxicity, withdrawal, or study completion, expected by April 2029.
1-10 of 20
1